Total Payments
$63,604
2024 Payments
$3,400
Companies
20
Transactions
78
Payment Breakdown by Category
Consulting$46,116 (72.5%)
Other$11,121 (17.5%)
Travel$3,820 (6.0%)
Food & Beverage$1,422 (2.2%)
Research$1,125 (1.8%)
Education$0.55 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $46,116 | 28 | 72.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,121 | 11 | 14.3% |
| Travel and Lodging | $3,820 | 17 | 6.0% |
| Honoraria | $2,000 | 1 | 3.1% |
| Food and Beverage | $1,422 | 19 | 2.2% |
| Unspecified | $1,125 | 1 | 1.8% |
| Education | $0.55 | 1 | 0.0% |
Payments by Type
General
$62,479
77 transactions
Research
$1,125
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $7,820 | 13 | $0 (2022) |
| Genentech USA, Inc. | $7,072 | 7 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $6,162 | 8 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $5,500 | 2 | $0 (2021) |
| Eisai Inc. | $5,448 | 7 | $0 (2023) |
| Halozyme Inc | $4,618 | 8 | $0 (2017) |
| Amgen Inc. | $4,523 | 7 | $0 (2023) |
| GlaxoSmithKline, LLC. | $4,225 | 2 | $0 (2021) |
| Gilead Sciences, Inc. | $3,040 | 1 | $0 (2021) |
| Intera Oncology, Inc | $2,500 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,400 | 4 | Janssen Scientific Affairs, LLC ($2,025) |
| 2023 | $7,091 | 6 | Amgen Inc. ($2,475) |
| 2022 | $5,970 | 6 | Exelixis Inc. ($2,310) |
| 2021 | $21,634 | 14 | GlaxoSmithKline, LLC. ($4,225) |
| 2020 | $1,348 | 2 | Amgen Inc. ($688.00) |
| 2019 | $6,597 | 6 | Merck Sharp & Dohme Corporation ($3,750) |
| 2018 | $7,649 | 15 | Genentech USA, Inc. ($4,321) |
| 2017 | $9,915 | 25 | Halozyme Inc ($4,618) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Intera Oncology, Inc | INTERA (Device) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | Intera Oncology, Inc | INTERA (Device) | Consulting Fee | Cash or cash equivalent | $275.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2024 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 04/22/2024 | Intera Oncology, Inc | INTERA (Device) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 09/05/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 03/13/2023 | Intera Oncology, Inc | Intera 3000 Implantable Pump (Device) | Consulting Fee | In-kind items and services | $1,125.00 | General |
| Category: Oncology | ||||||
| 02/22/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 02/21/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $110.78 | General |
| 11/04/2022 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $660.00 | General |
| Category: Oncology | ||||||
| 10/14/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,460.00 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2022 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 05/13/2022 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $660.00 | General |
| Category: Oncology | ||||||
| 02/25/2022 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $990.00 | General |
| Category: Oncology | ||||||
| 01/07/2022 | Novocure Inc. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 12/01/2021 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 11/19/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $3,547.50 | General |
| Category: Oncology | ||||||
| 10/20/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 09/03/2021 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $330.00 | General |
| Category: Oncology | ||||||
| 08/25/2021 | QED Therapeutics, Inc. | TRUSELTIQ (Drug) | — | Cash or cash equivalent | $1,125.00 | Research |
| Study: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations • Category: Cholangiocarcinoma | ||||||
| 07/22/2021 | Exelixis Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| 06/01/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| 04/12/2021 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $396.00 | General |
| Category: Oncology | ||||||
| 03/31/2021 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | QED Therapeutics, Inc. | $1,125 | 1 |
About Dr. Alan Venook, MD
Dr. Alan Venook, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487618831.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Venook, MD has received a total of $63,604 in payments from pharmaceutical and medical device companies, with $3,400 received in 2024. These payments were reported across 78 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($46,116).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Medical Oncology
- Location San Francisco, CA
- Active Since 04/13/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1487618831
Products in Payments
- Lenvima (Drug) $5,448
- OPDIVO (Biological) $5,275
- Avastin (Biological) $4,321
- LUMAKRAS (Drug) $3,124
- Cabometyx (Drug) $2,970
- Vitrakvi (Drug) $2,457
- CABOMETYX (Drug) $2,211
- RYBREVANT (Drug) $2,025
- BRAFTOVI (Drug) $1,460
- INTERA (Device) $1,375
- Intera 3000 Implantable Pump (Device) $1,125
- TRUSELTIQ (Drug) $1,125
- YERVOY (Biological) $825.00
- TUKYSA (Drug) $550.00
- Enhertu (Drug) $207.44
- IMFINZI (Drug) $75.00
- Lonsurf (Drug) $32.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736